Previously, some studies in prostate cancer, breast cancer, and gastric carcinomas also reported that TOP2A overexpression is not closely correlated with TOP2A amplification, in contrast to the strong correlation of HER2 overexpression with HER2 amplification [45, 49–52]. This evidence concerns the gene TOP2A and prostate cancer.